Valuation: Mendus AB

Market Cap 42Cr 4.34Cr 3.8Cr 3.5Cr 3.23Cr 6.14Cr 413.95Cr 6.24Cr 16Cr 203.93Cr 16Cr 16Cr 701.05Cr P/E 2026 *
-4.46x
P/E 2027 * -7.59x
Enterprise Value 9.71Cr 1.01Cr 88.1L 81.27L 75.06L 1.42Cr 96Cr 1.45Cr 3.81Cr 47Cr 3.78Cr 3.7Cr 162.69Cr EV / Sales 2026 *
10.8x
EV / Sales 2027 * 0.99x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day+5.57%
1 week+11.62%
Current month+17.79%
1 month+31.91%
3 months+36.40%
6 months+17.38%
Current year+21.79%
1 week 6.06
Extreme 6.06
7.24
1 month 5.1
Extreme 5.1
7.49
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 76 13/12/2019
Chief Executive Officer 54 16/03/2021
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/22/28Buy

Chief Technology Officer

10,000 0.0050%
24/22/24Buy

Chief Executive Officer

84,000 0.0421%
24/22/24Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+5.57%+11.62%-7.08%-33.91% 4.34Cr
+0.58%+2.06%+3.90%+10.40% 5.07TCr
-2.22%-1.25%+391.53%+591.38% 3.97TCr
-0.54%+0.39%+27.67%-3.89% 3.47TCr
-1.36%+0.35%+19.34%+58.83% 3.32TCr
+1.21%-4.58%+3.00%+37.03% 2.68TCr
-1.81%-1.48% - - 1.68TCr
+0.51%-3.47%+66.38%+125.61% 1.54TCr
+0.23%-0.58%+13.80%+19.56% 1.38TCr
-0.62%-3.09%+11.43%-29.93% 1.28TCr
Average +0.16%+0.41%+58.88%+86.12% 2.44TCr
Weighted average by Cap. -0.48%-0.23%+82.73%+126.11%

Financials

2026 *2027 *
Net sales 89.5L 9L 8L 7L 7L 13.13L 8.85Cr 13.35L 35.15L 4.36Cr 34.86L 34.1L 15Cr 22Cr 2.33Cr 2.04Cr 1.88Cr 1.74Cr 3.29Cr 222.11Cr 3.35Cr 8.82Cr 109.42Cr 8.74Cr 8.55Cr 376.16Cr
Net income -16Cr -1.69Cr -1.48Cr -1.36Cr -1.26Cr -2.39Cr -161.23Cr -2.43Cr -6.4Cr -79Cr -6.35Cr -6.21Cr -273.06Cr -1.86Cr -19.28L -16.87L -15.56L -14.37L -27.27L -18Cr -27.72L -73L -9.06Cr -72.41L -70.83L -31Cr
Net Debt -32Cr -3.33Cr -2.92Cr -2.69Cr -2.48Cr -4.71Cr -317.89Cr -4.79Cr -13Cr -156.6Cr -13Cr -12Cr -538.36Cr -20Cr -2.04Cr -1.79Cr -1.65Cr -1.52Cr -2.89Cr -194.91Cr -2.94Cr -7.74Cr -96Cr -7.67Cr -7.51Cr -330.1Cr
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
10/26/10 SEK 6.820 +5.57% 37,316
09/26/09 SEK 6.460 -2.12% 33,008
08/26/08 SEK 6.600 +1.54% 71,614
07/26/07 SEK 6.500 -4.27% 51,120
06/26/06 SEK 6.790 +11.13% 80,794
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.820SEK
Average target price
16.00SEK
Spread / Average Target
+134.60%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock